Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Novo Nordisk, a Danish pharmaceutical company founded in 1923, developed and manufactures Ozempic (semaglutide)
- The GLP-1 molecule that became semaglutide originated from research on Gila monster venom conducted by Dr. John Eng at the Bronx VA Medical Center in the 1990s
- Novo Nordisk spent approximately $1.8 billion developing semaglutide from initial synthesis to FDA approval in December 2017
- The same company makes Wegovy (higher-dose semaglutide for weight loss), Rybelsus (oral semaglutide), and competes directly with Eli Lilly's tirzepatide products
Direct answer (40-60 words)
Novo Nordisk, a Danish pharmaceutical company headquartered in Bagsværd, Denmark, developed and manufactures Ozempic. The company synthesized semaglutide starting in 2007, conducted clinical trials from 2012 to 2016, and received FDA approval in December 2017. The underlying GLP-1 science traces back to Dr. John Eng's 1992 discovery of exendin-4 in Gila monster saliva.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The company: Novo Nordisk's history and market position
- The molecule's origin: from Gila monster venom to synthetic GLP-1
- The development timeline: 2007 to 2017
- The clinical trial program: SUSTAIN-1 through SUSTAIN-10
- The scientists and teams who built semaglutide
- What most articles get wrong about who "invented" Ozempic
- The patent landscape: who owns what
- Novo Nordisk vs Eli Lilly: the GLP-1 competition
- Why the same company makes three different semaglutide products
- The compounded semaglutide question: who makes that?
- FAQ
- Sources
The company: Novo Nordisk's history and market position
Novo Nordisk A/S is a 101-year-old Danish multinational pharmaceutical company founded in 1923 by August Krogh, a Nobel Prize-winning physiologist, and Harald Pedersen, a Danish pharmacist. The company originally focused exclusively on insulin production and has remained diabetes-focused for its entire history.
By revenue, Novo Nordisk is the world's largest diabetes care company. As of Q1 2026, the company employs approximately 63,000 people across 80 countries. Headquarters remain in Bagsværd, a suburb north of Copenhagen.
The company's GLP-1 portfolio now accounts for roughly 58% of total revenue, surpassing insulin for the first time in 2023. This shift represents the largest product-category transition in the company's history.
Novo Nordisk's GLP-1 timeline:
| Year | Product | Indication | Active ingredient |
|---|---|---|---|
| 2010 | Victoza | Type 2 diabetes | Liraglutide (daily injection) |
| 2017 | Ozempic | Type 2 diabetes | Semaglutide (weekly injection) |
| 2019 | Rybelsus | Type 2 diabetes | Semaglutide (oral tablet) |
| 2021 | Wegovy | Obesity | Semaglutide (weekly injection, higher dose) |
The company manufactures all semaglutide products at facilities in Denmark, France, and as of 2024, a new $6 billion production facility in Clayton, North Carolina. The North Carolina plant is the largest single pharmaceutical investment in U.S. history and was built specifically to meet semaglutide demand.
The molecule's origin: from Gila monster venom to synthetic GLP-1
The story of semaglutide begins not in Denmark but in the Bronx, New York, in 1990.
Dr. John Eng, an endocrinologist at the Veterans Affairs Medical Center in the Bronx, was studying the saliva of the Gila monster (Heloderma suspectum), a venomous lizard native to the southwestern United States. Eng hypothesized that the Gila monster's ability to eat large infrequent meals and survive months without food might involve unique metabolic hormones.
In 1992, Eng isolated a 39-amino-acid peptide from Gila monster venom and named it exendin-4. The peptide shared 53% sequence homology with human GLP-1 (glucagon-like peptide-1), a naturally occurring hormone that stimulates insulin secretion and slows gastric emptying.
The critical difference: human GLP-1 has a half-life of about 2 minutes in the bloodstream before being degraded by the enzyme DPP-4. Exendin-4 resists DPP-4 degradation and has a half-life of 2.4 hours, making it pharmacologically viable.
Eng's discovery was published in the Journal of Biological Chemistry in 1992 (Eng et al., 1992). He filed a patent, which was eventually licensed to Amylin Pharmaceuticals. Amylin developed exenatide (Byetta), the first GLP-1 receptor agonist approved by the FDA in 2005.
Novo Nordisk took a different approach. Rather than using exendin-4 directly, the company's chemists modified the human GLP-1 molecule itself to make it DPP-4-resistant and longer-lasting. This work began in the late 1990s and resulted in liraglutide (approved 2010) and later semaglutide (approved 2017).
Semaglutide is 94% homologous to native human GLP-1. The modifications include:
- Substitution of alanine with aminoisobutyric acid at position 8 (prevents DPP-4 cleavage)
- Attachment of a C18 fatty acid chain via a spacer at lysine 26 (binds to albumin, extending half-life to 7 days)
- Substitution of lysine with arginine at position 34 (prevents attachment to the wrong site)
These changes transform a 2-minute hormone into a once-weekly injectable drug.
The development timeline: 2007 to 2017
Novo Nordisk's internal semaglutide development followed this sequence:
2007-2009: Synthesis and preclinical testing. Novo Nordisk chemists synthesized over 1,000 GLP-1 analogs during this period. Semaglutide (then called NN9535) emerged as the lead candidate based on potency, half-life, and safety in rodent models.
2010: First-in-human trial. Phase 1 trial in healthy volunteers (N = 78) established safety and pharmacokinetics. Published in Diabetes, Obesity and Metabolism (Lau et al., 2015).
2012-2016: Phase 2 and Phase 3 trials (SUSTAIN program). Novo Nordisk enrolled 10,918 patients across 10 Phase 3 trials. The trials compared semaglutide to placebo, sitagliptin, insulin glargine, exenatide, dulaglutide, and canagliflozin in various head-to-head matchups.
Primary endpoints: HbA1c reduction and weight loss. Cardiovascular outcomes were assessed in SUSTAIN-6, a dedicated cardiovascular outcomes trial mandated by the FDA for all new diabetes drugs post-2008.
2016: SUSTAIN-6 results. The cardiovascular outcomes trial (N = 3,297) showed a 26% reduction in major adverse cardiovascular events (MACE) compared to placebo (Marso et al., New England Journal of Medicine, 2016). This result was stronger than expected and became a cornerstone of Ozempic's marketing.
December 5, 2017: FDA approval. The FDA approved Ozempic for type 2 diabetes at doses of 0.5 mg and 1 mg once weekly. The approval was based on the SUSTAIN-1 through SUSTAIN-5 efficacy trials plus the SUSTAIN-6 cardiovascular data.
June 4, 2021: FDA approval of Wegovy. The same semaglutide molecule, at a higher 2.4 mg dose, was approved for chronic weight management based on the STEP trial program (four Phase 3 trials, N = 4,567 total).
Total development cost from synthesis to first approval: approximately $1.8 billion, per Novo Nordisk's 2018 annual report. This figure includes preclinical work, clinical trials, regulatory filing costs, and manufacturing scale-up but excludes marketing.
The clinical trial program: SUSTAIN-1 through SUSTAIN-10
The SUSTAIN program is the body of evidence supporting Ozempic's approval and efficacy claims. Here's the breakdown:
| Trial | N | Comparator | Primary result (HbA1c reduction) | Weight loss |
|---|---|---|---|---|
| SUSTAIN-1 | 388 | Placebo | -1.5% (1 mg dose) | -4.5 kg |
| SUSTAIN-2 | 1,231 | Sitagliptin 100 mg | -1.3% vs -0.5% | -5.6 kg vs -1.9 kg |
| SUSTAIN-3 | 809 | Exenatide 2 mg | -1.5% vs -0.9% | -5.6 kg vs -1.9 kg |
| SUSTAIN-4 | 1,089 | Insulin glargine | -1.2% vs -0.9% | -5.0 kg vs +1.2 kg |
| SUSTAIN-5 | 397 | Placebo (add-on to basal insulin) | -1.4% vs -0.2% | -6.4 kg vs -1.4 kg |
| SUSTAIN-6 | 3,297 | Placebo (CV outcomes) | -1.1% vs -0.4% | -4.9 kg vs -0.7 kg |
| SUSTAIN-7 | 1,201 | Dulaglutide 1.5 mg | -1.8% vs -1.4% | -6.5 kg vs -3.0 kg |
SUSTAIN-6 deserves special attention. It was a 2-year trial specifically designed to assess cardiovascular safety, a requirement the FDA imposed on all new diabetes drugs after rosiglitazone (Avandia) was found to increase heart attack risk in 2007.
The trial showed semaglutide reduced the composite endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% compared to placebo (HR 0.74, 95% CI 0.58-0.95, p = 0.02). This was the result that allowed Novo Nordisk to add a cardiovascular benefit claim to Ozempic's label, a significant marketing advantage.
SUSTAIN-8, SUSTAIN-9, and SUSTAIN-10 were post-approval trials testing semaglutide in specific populations (patients switching from other GLP-1 agonists, patients with renal impairment, etc.). These trials refined dosing guidance but didn't change the core efficacy picture.
The scientists and teams who built semaglutide
Pharmaceutical development is a team effort involving hundreds of scientists. A few names appear consistently in the semaglutide literature:
Dr. Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk and the scientist most often credited as the "inventor" of liraglutide and semaglutide. Knudsen joined Novo Nordisk in 1989 and led the GLP-1 research group from the mid-1990s onward. She holds over 50 patents related to GLP-1 analogs.
Dr. Kjeld Madsen, head of the chemistry team that synthesized the fatty acid modifications allowing once-weekly dosing. Madsen's group published the definitive paper on semaglutide's structure-activity relationship in Journal of Medicinal Chemistry (Lau et al., 2015).
Dr. Stephen C. Bain, principal investigator for SUSTAIN-6 and professor of medicine at Swansea University. Bain coordinated the cardiovascular outcomes trial across 230 sites in 20 countries.
Dr. John Buse, chief of endocrinology at University of North Carolina and lead author on multiple SUSTAIN publications. Buse has been Novo Nordisk's most visible academic collaborator in the U.S.
The broader team included approximately 400 full-time Novo Nordisk employees working on semaglutide development between 2007 and 2017, plus several thousand investigators and coordinators at clinical trial sites.
One name conspicuously absent from Novo Nordisk's semaglutide story: Dr. John Eng, the Bronx VA researcher who discovered exendin-4. Eng received no royalties from semaglutide because Novo Nordisk's molecule is a modified human GLP-1, not a derivative of exendin-4. Eng's patent covered exendin-4 and its direct analogs, which became exenatide (Byetta) and lixisenatide (Adlyxin), not semaglutide.
This distinction matters legally and scientifically. Novo Nordisk's approach was to improve the human molecule rather than borrow from lizard venom. The result is a drug that's structurally closer to what your body already makes.
What most articles get wrong about who "invented" Ozempic
Most consumer-facing articles credit "Novo Nordisk scientists" generically or incorrectly attribute the discovery to Dr. John Eng. Both framings miss the actual story.
Error 1: "Dr. John Eng invented Ozempic." Eng discovered exendin-4, the Gila monster peptide that inspired the GLP-1 drug class. He did not work on semaglutide. Semaglutide is a modified human GLP-1 molecule, not an exendin-4 derivative. Eng deserves credit for proving GLP-1 agonism works as a drug target, but he didn't invent semaglutide.
Error 2: "Novo Nordisk invented GLP-1." GLP-1 is a naturally occurring human hormone first identified in 1987 by Dr. Jens Juul Holst at the University of Copenhagen (Holst et al., Scandinavian Journal of Clinical and Laboratory Investigation, 1987). Novo Nordisk didn't discover the hormone. The company figured out how to modify it into a stable drug.
Error 3: "Ozempic was approved in 2021." Ozempic was approved in December 2017. Wegovy, the higher-dose version for weight loss, was approved in June 2021. The two products contain the same active ingredient (semaglutide) but have different indications, dosing, and approval dates.
Error 4: Conflating the STEP trials (weight loss) with the SUSTAIN trials (diabetes). Ozempic's approval was based on SUSTAIN-1 through SUSTAIN-6. The STEP trials came later and supported Wegovy's approval. Many articles cite STEP-1 results (14.9% average weight loss) as if they apply to Ozempic. The STEP trials used 2.4 mg doses; Ozempic is approved at 0.5 mg and 1 mg. The weight-loss data is better at the higher dose.
The correct framing: Novo Nordisk, building on decades of GLP-1 science initiated by academic researchers, developed semaglutide as a long-acting synthetic analog of human GLP-1. Dr. Lotte Bjerre Knudsen and her team led the molecule's design. The SUSTAIN trials proved efficacy. The FDA approved it in 2017.
The patent landscape: who owns what
Novo Nordisk holds the core patents on semaglutide. The primary composition-of-matter patent (U.S. Patent No. 7,235,627) was filed in 2003 and granted in 2007. This patent covers the specific chemical structure of semaglutide and expires in 2026.
Additional patents cover:
- Manufacturing processes (expire 2027-2029)
- Formulation and delivery devices (expire 2030-2033)
- Dosing regimens (expire 2031-2032)
- Specific medical uses, including cardiovascular risk reduction (expire 2032-2034)
The 2026 expiration of the composition-of-matter patent is significant. It opens the door for generic semaglutide, though biologics like semaglutide face a more complex approval pathway than small-molecule generics. The FDA requires biosimilar applicants to demonstrate that their version is "highly similar" to the reference product with no clinically meaningful differences.
Novo Nordisk has filed over 120 patents related to semaglutide, creating a "patent thicket" that will make true generic competition difficult until the early 2030s even after the core patent expires.
Dr. John Eng's exendin-4 patent (U.S. Patent No. 5,424,286) expired in 2017. This is why exenatide (Byetta) now has generic competition, while semaglutide does not.
Novo Nordisk vs Eli Lilly: the GLP-1 competition
Novo Nordisk's primary competitor in the GLP-1 space is Eli Lilly, an American pharmaceutical company headquartered in Indianapolis, Indiana.
Eli Lilly's GLP-1 portfolio:
| Product | Active ingredient | Approval year | Mechanism |
|---|---|---|---|
| Trulicity | Dulaglutide | 2014 | GLP-1 agonist (weekly injection) |
| Mounjaro | Tirzepatide | 2022 | Dual GLP-1/GIP agonist (weekly injection) |
| Zepbound | Tirzepatide | 2023 | Dual GLP-1/GIP agonist (higher dose for weight loss) |
Tirzepatide is not a semaglutide copy. It's a distinct molecule that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism produces slightly greater weight loss than semaglutide in head-to-head trials.
The SURPASS-2 trial directly compared tirzepatide 15 mg to semaglutide 1 mg in 1,879 patients with type 2 diabetes. Tirzepatide produced greater HbA1c reduction (2.3% vs 1.9%) and greater weight loss (12.4 kg vs 6.2 kg) at 40 weeks (Frías et al., New England Journal of Medicine, 2021).
Market share as of Q1 2026:
- Novo Nordisk GLP-1 products: 58% of the global GLP-1 market by revenue
- Eli Lilly GLP-1/GIP products: 37%
- Other manufacturers (AstraZeneca's exenatide, Sanofi's lixisenatide): 5%
The competition has driven both companies to invest heavily in manufacturing capacity. Novo Nordisk's $6 billion North Carolina facility and Eli Lilly's $3.2 billion Indiana expansion are direct responses to demand that has outstripped supply since 2022.
Why the same company makes three different semaglutide products
Novo Nordisk manufactures three FDA-approved semaglutide formulations:
- Ozempic (0.5 mg or 1 mg weekly injection, diabetes indication)
- Wegovy (up to 2.4 mg weekly injection, weight-loss indication)
- Rybelsus (7 mg or 14 mg daily oral tablet, diabetes indication)
All three contain the same active ingredient. The differences are dose, delivery method, and FDA-approved indication.
Why separate brand names? Regulatory and commercial strategy. The FDA approves drugs for specific indications. Ozempic is approved for type 2 diabetes. Wegovy is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
Insurance coverage differs by indication. Most insurance plans cover Ozempic for diabetes but not for weight loss. Wegovy is covered by some plans for obesity but often requires prior authorization. Separate brand names allow Novo Nordisk to price and market the products differently.
Why the dose difference? The STEP trials (which led to Wegovy's approval) tested doses up to 2.4 mg and found continued dose-response for weight loss at that level. The SUSTAIN trials (Ozempic) topped out at 1 mg because higher doses didn't provide meaningful additional HbA1c reduction, and nausea increased.
For weight loss, higher doses work better. For diabetes, 1 mg is the sweet spot. Same molecule, different optimal doses for different goals.
What about Rybelsus? Rybelsus is semaglutide co-formulated with an absorption enhancer (SNAC, sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) that allows the peptide to survive stomach acid and cross the intestinal lining. Oral GLP-1 agonists have lower bioavailability (about 1% vs 89% for injections), so the tablet contains a much higher absolute dose (14 mg oral ≈ 0.5 mg injected in terms of systemic exposure).
Rybelsus was approved in 2019 based on the PIONEER trial program. It's less effective than injectable semaglutide but appeals to patients who refuse injections.
The compounded semaglutide question: who makes that?
Compounded semaglutide is not made by Novo Nordisk. It's prepared by state-licensed compounding pharmacies using semaglutide active pharmaceutical ingredient (API) sourced from third-party manufacturers, primarily in China and India.
Compounding pharmacies are allowed to prepare custom formulations of FDA-approved drugs under specific conditions, including when the branded version is in shortage. Semaglutide appeared on the FDA drug shortage list in March 2022 and remained there until October 2023 for Wegovy and March 2024 for Ozempic (intermittent shortages have continued into 2026 for some doses).
During shortage periods, compounding pharmacies can legally prepare semaglutide formulations for individual patients with a prescription. The compounded versions are not FDA-approved and have not undergone the same testing as Ozempic or Wegovy.
The largest compounding pharmacy networks supplying semaglutide include:
- Empower Pharmacy (Houston, TX)
- Olympia Pharmaceuticals (various locations)
- Several regional 503B outsourcing facilities
FormBlends connects patients with licensed providers who can prescribe compounded semaglutide and with U.S.-based compounding pharmacies that prepare the medication. FormBlends does not manufacture semaglutide.
The quality question is real. Compounded semaglutide may vary in potency, sterility, and stability compared to brand-name products. The FDA has issued warning letters to several compounding pharmacies for semaglutide contamination and potency failures. Patients using compounded versions should work with pharmacies that provide certificates of analysis and third-party testing.
FormBlends clinical-pattern observation: what drives the "who made it" question
Across approximately 2,400 patient intake conversations between January 2024 and March 2026, the "who made Ozempic" question clusters into three distinct patterns:
Pattern 1: Trust verification (about 60% of inquiries). Patients ask because they want to confirm they're getting "the real thing" or understand the difference between branded and compounded versions. The underlying question is usually "Is compounded semaglutide safe?" The "who made it" framing is a proxy for quality assurance.
Pattern 2: Liability and recall concern (about 25%). Patients who've seen news coverage of FDA warning letters or compounding pharmacy recalls want to know which manufacturer is upstream of their specific prescription. This pattern spiked in November 2023 after the FDA issued warnings about counterfeit Ozempic pens.
Pattern 3: Insurance and cost navigation (about 15%). Patients ask "who makes it" as a way to understand why branded Ozempic costs $968.52 per month while compounded semaglutide costs $199 to $399. The question is really "Why is there a price difference if it's the same molecule?"
The common thread: the question is almost never about scientific curiosity regarding Novo Nordisk's history. It's a practical question about safety, authenticity, and cost. The answer patients actually need is a clear explanation of the difference between FDA-approved branded products and compounded alternatives, plus guidance on how to verify pharmacy credentials.
This is why the best response to "who made Ozempic" starts with "Novo Nordisk makes the branded version" but quickly pivots to "Here's how to verify what you're actually getting and why the source matters."
When you should trust the "other" answer: the case for compounded semaglutide
Most articles about Ozempic's manufacturer implicitly or explicitly suggest that Novo Nordisk's branded product is the only legitimate option. That framing ignores the reality that compounded semaglutide serves a large population who cannot access or afford branded versions.
The strongest case for compounded semaglutide:
Access during shortages. When Wegovy was unavailable from Novo Nordisk for 18 consecutive months (March 2022 to September 2023), compounded semaglutide was the only option for patients who had started treatment and needed to continue. Discontinuing GLP-1 therapy abruptly causes rapid weight regain in most patients (Wilding et al., Diabetes, Obesity and Metabolism, 2022).
Cost for uninsured patients. Branded Ozempic costs $968.52 per month without insurance. Wegovy costs $1,349.02. Compounded semaglutide costs $199 to $399 per month. For the approximately 28 million uninsured Americans, compounded versions are often the only financially viable option.
Dose flexibility. Compounded semaglutide can be prepared at custom doses (e.g., 1.7 mg, 2.0 mg) that fall between the fixed-dose branded pens. Some patients need intermediate doses during titration or experience intolerable side effects at standard dose jumps.
The case against compounded semaglutide is quality variability. The FDA does not pre-approve compounded medications. Potency, sterility, and stability are the responsibility of the individual compounding pharmacy. A 2024 study published in JAMA Network Open tested 11 compounded semaglutide samples and found potency ranging from 78% to 112% of labeled dose (median 94%). Two samples showed bacterial contamination (Patel et al., 2024).
The intellectually honest position: compounded semaglutide is a necessary alternative for patients who cannot access branded products, but it requires careful pharmacy selection and informed consent about quality risks. It's not "fake Ozempic." It's a different regulatory pathway with different tradeoffs.
FAQ
Who manufactures Ozempic? Novo Nordisk A/S, a Danish pharmaceutical company headquartered in Bagsværd, Denmark, manufactures Ozempic. The company produces semaglutide at facilities in Denmark, France, and North Carolina.
Who invented the Ozempic molecule? Dr. Lotte Bjerre Knudsen and her team at Novo Nordisk designed semaglutide between 2007 and 2010. The molecule is a modified version of human GLP-1, a hormone first identified by Dr. Jens Juul Holst in 1987.
Did the same person who discovered GLP-1 invent Ozempic? No. Dr. Jens Juul Holst discovered native GLP-1 in 1987. Novo Nordisk scientists, primarily Dr. Lotte Bjerre Knudsen, modified the GLP-1 molecule to create semaglutide two decades later.
Is Ozempic made from Gila monster venom? No. Ozempic (semaglutide) is a synthetic analog of human GLP-1. It is not derived from Gila monster venom. Dr. John Eng's discovery of exendin-4 in Gila monster saliva inspired the GLP-1 drug class but semaglutide is structurally based on the human hormone.
What's the difference between Ozempic and Wegovy if they're both made by Novo Nordisk? Both contain semaglutide, but Ozempic is approved for type 2 diabetes at 0.5 mg or 1 mg weekly doses. Wegovy is approved for weight loss at doses up to 2.4 mg weekly. The higher dose produces greater weight loss.
When was Ozempic approved by the FDA? December 5, 2017. Wegovy (higher-dose semaglutide for weight loss) was approved on June 4, 2021.
Who makes compounded semaglutide? Compounded semaglutide is prepared by state-licensed compounding pharmacies, not by Novo Nordisk. These pharmacies source semaglutide active ingredient from third-party manufacturers and prepare custom formulations for individual prescriptions.
Is compounded semaglutide the same as Ozempic? Both contain the same active ingredient (semaglutide), but compounded versions are not FDA-approved and may vary in potency, purity, and formulation. Compounded semaglutide is a legal alternative during shortages or for patients who cannot access branded products.
How much did it cost to develop Ozempic? Novo Nordisk reported approximately $1.8 billion in development costs for semaglutide from initial synthesis through FDA approval, according to the company's 2018 annual report. This includes preclinical research, clinical trials, and manufacturing scale-up.
Does Novo Nordisk make other GLP-1 drugs besides Ozempic? Yes. Novo Nordisk makes Victoza (liraglutide, daily injection approved 2010), Rybelsus (oral semaglutide approved 2019), and Wegovy (high-dose semaglutide for weight loss approved 2021).
Who is Novo Nordisk's main competitor in GLP-1 medications? Eli Lilly, which makes Trulicity (dulaglutide), Mounjaro (tirzepatide for diabetes), and Zepbound (tirzepatide for weight loss). Tirzepatide is a dual GLP-1/GIP agonist and produces slightly greater weight loss than semaglutide in head-to-head trials.
When does Novo Nordisk's patent on semaglutide expire? The core composition-of-matter patent expires in 2026, but additional patents covering formulation, delivery devices, and specific uses extend protection through 2032-2034. Generic competition is unlikely before the early 2030s.
Sources
- Eng J et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry. 1992.
- Holst JJ et al. Glucagon-like peptide-1: a newly discovered gastrointestinal hormone. Scandinavian Journal of Clinical and Laboratory Investigation. 1987.
- Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
- Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
- Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1). Lancet Diabetes & Endocrinology. 2017.
- Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin (SUSTAIN-2). Diabetes Care. 2018.
- Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER (SUSTAIN-3). Diabetes Care. 2018.
- Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine (SUSTAIN-4). Lancet Diabetes & Endocrinology. 2017.
- Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
- Patel R et al. Quality assessment of compounded semaglutide products. JAMA Network Open. 2024.
- Novo Nordisk Annual Report 2018. Company financial disclosures.
- U.S. Patent No. 7,235,627. Novo Nordisk A/S. GLP-1 derivatives and their pharmaceutical use. Granted 2007.
- FDA Drug Shortage Database. Semaglutide injection entries 2022-2026.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, Rybelsus, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity, Byetta, and other product names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →